Most companies losing a million customers call it a crisis. UnitedHealth Group is calling it a strategy.
Medicare’s annual open enrollment period begins October 15 this year, and runs through December 7. The window matters because plan choice is shrinking. The typical Medicare beneficiary can now choose from 28 Medicare Advantage prescription drug plans, down from 32 in 2026; counting all plan types, the average falls from 39 to 35. That is well below the peak of 36 prescription-drug plans available in 2024.
UnitedHealth is at the center of this contraction, and that is precisely the point.
The Retreat That Reads Like a Play
UnitedHealth Group is exiting 228 counties and entering just 9 new ones, while Humana is leaving 62 counties and entering 4, according to KFF. Healthcare Dive’s analysis of CMS landscape data and industry research also points to a broad pullback by major carriers: UnitedHealthcare, the largest Medicare Advantage insurer, is nixing about 690 plans and exiting 63 counties.
UnitedHealth confirmed approximately 390,000 members are in plans being discontinued for 2027. Across the market, KFF reports 638,000 people, about 1% of all Medicare beneficiaries, will have no Medicare Advantage plan option for 2027, up from 399,000 this year.
This is not retreat. It is culling. By shedding unprofitable counties and discontinuing plans, UnitedHealth gets to reassemble its 2027 book with only the members whose cost profile it can manage. UnitedHealth Group covered roughly 26% of all Medicare Advantage enrollees in 2026, the largest share of any carrier; together with Humana at roughly 20%, the two companies accounted for about 46% of the entire Medicare Advantage market, according to KFF. Surrendering county footprint while holding national dominance is a meaningful lever to pull when margins are under pressure.
What’s Changing the Math
Insurers have been laser-focused on resuscitating flagging margins after years of unexpectedly high medical spending. For UnitedHealth, that showed up clearly in the second-quarter financials. Consolidated revenues for Q2 2026 were $112.0 billion with earnings from operations of $8.0 billion and a net margin of 4.9%. The company raised its full-year 2026 adjusted net earnings outlook to between $19.50 and $20.00 per share.
UnitedHealth is scheduled to release its third-quarter 2026 results Tuesday, October 13, 2026, before the market opens. Analysts had expected earnings of around $4.14 per share and revenue of $111.31 billion. The 2027 star ratings, released by CMS on October 8, add another layer. The star ratings released in October are used in the following year’s Medicare Advantage quality bonus payments, meaning the 2027 star ratings affect 2028 bonus payments, and lower ratings can reduce future bonuses and pressure plan competitiveness.
Bull Case, Bear Case
The bull case is straightforward: a smaller, more profitable Medicare book. Fewer members in marginal counties means a higher-quality risk pool and easier medical cost management. KFF’s 2027 plan-availability analysis shows the average beneficiary will have fewer Medicare Advantage options than in 2026, and major carriers are pulling back in many places. UnitedHealth is not alone in this pricing cycle, but it is doing it from the largest base.
The bear case centers on the star ratings slide. CMS said approximately 37% of MA-PD contracts that will be offered in 2027 earned four stars or higher for their 2027 overall rating, down from 44.4% in 2026. Bonus payments hinge on hitting that threshold, and losing quality star ratings can pressure plan competitiveness, especially below 4.0, because plans rated four stars or higher qualify for Medicare quality bonus payments that will affect 2028 reimbursements. A sustained ratings decline would undercut the economics that make the remaining portfolio worth keeping.
What to Watch
Three metrics matter most over the next 90 days: whether UnitedHealth’s medical care ratio stays in the range management guided for Q3 (analysts had penciled in roughly 90.1%); whether full-year earnings guidance holds at $19.50 to $20.00 adjusted; and how the company frames the 2027 star ratings when it speaks to investors after it reports results on October 13.
The answer to the last question matters beyond UNH. Humana, CVS Aetna, and Elevance Health all face the same structural tension: a government program whose reimbursement rates have lagged medical inflation, forcing every major player to choose between market share and margin. UnitedHealth has chosen margin. Whether that choice looks prescient or premature will depend on how many of the seniors it pushed out find their way back.
